Der Internist

, Volume 59, Issue 4, pp 401–409 | Cite as

Aktuelle Arzneimitteltherapie der Hepatitis C

Sinnvolle Therapiealgorithmen unter Berücksichtigung ökonomischer Aspekte
Arzneimitteltherapie
  • 220 Downloads

Zusammenfassung

Die Therapie der chronischen Hepatitis-C-Virus(HCV)-Infektion hat sich seit der Zulassung der neuen direkt antiviral wirksamen Medikamente grundlegend verändert. Die Welle der Einführung neuer Substanzen ist seit Sommer 2017 vorerst abgeschlossen. Abhängig vom HCV-Genotyp und dem Schweregrad der Lebererkrankung sind mit einer meist nur 8‑ bis 12-wöchigen antiviralen Therapie Ausheilungsraten von über 95 % bei chronisch HCV-infizierten Patienten die Regel. Die Auswahl der Substanzen bzw. deren Kombination richtet sich unter anderem nach dem Status der Vortherapie, dem Stadium der Leberfibrose, dem HCV-Genotyp bzw. -Subtyp, der Ausgangsviruslast und der Nierenfunktion. Heute kann annähernd jedem Patienten eine kurative und weitestgehend nebenwirkungsfreie Behandlungsmöglichkeit angeboten werden. Die Qualität der Behandlung unter Berücksichtigung des Gebots der Wirtschaftlichkeit ist für Deutschland eindrucksvoll im Deutschen Hepatitis C-Register bestätigt worden. Erste Daten zeigen bereits eine Reduktion klinischer Komplikationen der chronischen Lebererkrankung durch eine Ausheilung der HCV-Infektion.

Schlüsselwörter

Chronische Hepatitis C Akute Hepatitis C Direkt antiviral wirksame Medikamente Interferon-α Behandlungskosten 

Current drug treatment of hepatitis C

Useful therapy algorithms taking into consideration economical aspects

Abstract

Treatment of chronic hepatitis C (HCV) has changed dramatically since the approval of the direct-acting antivirals (DAA). Depending on the HCV genotype and the stage of liver disease, sustained HCV clearance can be achieved in more than 95% of patients with a treatment duration of 8–12 weeks in most of the cases. The selection and combination of the drugs depends on previous antivirals therapies, the stage of liver fibrosis, HCV genotype and subtype, viral load at baseline, and renal function. Nowadays, potent antiviral therapy with minimal side effects can be offered to almost every patient. In the real-world setting, a high quality of HCV therapy considering economic aspects has been documented in the German Hepatitis C Registry. A reduction of clinical complications of chronic liver disease by clearance of HCV has already been documented.

Keywords

Hepatitis C, chronic Hepatitis C, acute Antiviral agents, direct-acting Interferon-α Costs, treatment 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Deterding: Reisekostenerstattung und Vortragshonorare von AbbVie, MSD/Merck. M.P. Manns (Stand Juli 2017): Forschungsgelder, Beratungshonorare, Vortragshonorare und Reisekostenerstattung von Roche, Bristol Myers Squibb, Gilead, Merck (MSD), Janssen, AbbVie. Forschungsgelder und Beratungshonorare von Novartis. Forschungsgelder, Beratungshonorare und Reisekostenerstattung von GlaxoSmithKline. H. Wedemeyer: Honorare für Beratungstätigkeit oder Vorträge (vergangene 5 Jahre) von Abbott, AbbVie, BMS, Boehringer Ingelheim, Gilead, JJ/Janssen-Cilag, Merck/Schering-Plough, Novartis, Roche, Roche Diagnostics, Siemens, Transgene. Forschungsgelder von Abbott, AbbVie, BMS, Gilead, Merck, Novartis, Roche, Roche Diagnostics, Siemens.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Gerlach JT, Diepolder HM, Zachoval R et al (2003) Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 125:80–88CrossRefPubMedGoogle Scholar
  2. 2.
    Wiese M, Grungreiff K, Guthoff W et al (2005) Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany—a 25-year multicenter study. J Hepatol 43:590–598CrossRefPubMedGoogle Scholar
  3. 3.
    Grebely J, Prins M, Hellard M et al (2012) Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine. Lancet Infect Dis 12:408–414CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Deterding K, Gruner N, Buggisch P et al (2013) Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial. Lancet Infect Dis 13:497–506CrossRefPubMedGoogle Scholar
  5. 5.
    Polaris Observatory HCV Collaborators (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161–176CrossRefGoogle Scholar
  6. 6.
    Stanaway JD, Flaxman AD, Naghavi M et al (2016) The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 388:1081–1088CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Wedemeyer H (2015) Towards interferon-free treatment for all HCV genotypes. Lancet 385:2443–2445CrossRefPubMedGoogle Scholar
  8. 8.
    Honer Zu Siederdissen C, Maasoumy B, Marra F et al (2016) Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis 62:561–567CrossRefPubMedGoogle Scholar
  9. 9.
    Honer Zu Siederdissen C, Schlevogt B, Solbach P et al (2017) Real-world effect of ribavirin on quality of life in HCV-infected patients receiving interferon-free treatment. Liver Int.  https://doi.org/10.1111/liv.13601 PubMedGoogle Scholar
  10. 10.
    Höner zu Siederdissen C, Buggisch P, Böker K et al (2017) Treatment of hepatitis C genotype 1 infection in Germany: effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterol J.  https://doi.org/10.1177/2050640617716607 PubMedPubMedCentralGoogle Scholar
  11. 11.
    Welzel TM, Petersen J, Herzer K et al (2016) Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut 65:1861–1870CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Buggisch P, Vermehren J, Mauss S et al (2017) Real-world effectiveness of 8‑week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol.  https://doi.org/10.1016/j.jhep.2017.11.009 PubMedGoogle Scholar
  13. 13.
    Afdhal N, Reddy KR, Nelson DR et al (2014) Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 370:1483–1493CrossRefPubMedGoogle Scholar
  14. 14.
    Charlton M, Everson GT, Flamm SL et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:649–659CrossRefPubMedGoogle Scholar
  15. 15.
    Wedemeyer H, Craxi A, Zuckerman E et al (2017) Real-world effectiveness of ombitasvir/paritaprevir/ritonavir+/-dasabuvir+/-ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: a meta-analysis. J Viral Hepat 24:936–943CrossRefPubMedGoogle Scholar
  16. 16.
    Welzel TM, Hinrichsen H, Sarrazin C et al (2017) Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry. J Viral Hepat 24:840–849CrossRefPubMedGoogle Scholar
  17. 17.
    Poordad F, Nelson DR, Feld JJ et al (2017) Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced child-pugh A cirrhosis—a pooled analysis. J Hepatol 67:700–707CrossRefPubMedGoogle Scholar
  18. 18.
    Welzel TM, Asselah T, Dumas EO et al (2017) Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial. Lancet Gastroenterol Hepatol 2:494–500CrossRefPubMedGoogle Scholar
  19. 19.
    Feld JJ, Jacobson IM, Hezode C et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373:2599–2607CrossRefPubMedGoogle Scholar
  20. 20.
    Curry MP, O’Leary JG, Bzowej N et al (2015) Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med 373:2618–2628CrossRefPubMedGoogle Scholar
  21. 21.
    Zeuzem S, Ghalib R, Reddy KR et al (2015) Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1–13CrossRefPubMedGoogle Scholar
  22. 22.
    Roth D, Nelson DR, Bruchfeld A et al (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4‑5 chronic kidney disease (the C‑SURFER study): a combination phase 3 study. Lancet 386:1537–1545CrossRefPubMedGoogle Scholar
  23. 23.
    Gane E, Lawitz E, Pugatch D et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377:1448–1455CrossRefPubMedGoogle Scholar
  24. 24.
    Bourliere M, Gordon SC, Flamm SL et al (2017) Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376:2134–2146CrossRefPubMedGoogle Scholar
  25. 25.
    Jacobson IM, Lawitz E, Gane EJ et al (2017) Efficacy of 8 weeks of sofosbuvir, velpatasvir, and voxilaprevir in patients with chronic HCV infection: 2 phase 3 randomized trials. Gastroenterology 153:113–122CrossRefPubMedGoogle Scholar
  26. 26.
    Foster GR, Afdhal N, Roberts SK et al (2015) Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 373:2608–2617CrossRefPubMedGoogle Scholar
  27. 27.
    Wyles D, Poordad F, Wang S et al (2017) Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology.  https://doi.org/10.1002/hep.29541 Google Scholar
  28. 28.
    Jaeckel E, Cornberg M, Wedemeyer H et al (2001) Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 345:1452–1457CrossRefPubMedGoogle Scholar
  29. 29.
    Wiegand J, Deterding K, Cornberg M, Wedemeyer H (2008) Treatment of acute hepatitis C: the success of monotherapy with (pegylated) interferon alpha. J Antimicrob Chemother 62:860–865CrossRefPubMedGoogle Scholar
  30. 30.
    Dore GJ, Hellard M, Matthews GV et al (2010) Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 138:123–135 (e1–2)CrossRefPubMedGoogle Scholar
  31. 31.
    Deterding K, Spinner CD, Schott E et al (2017) Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Lancet Infect Dis 17:215–222CrossRefPubMedGoogle Scholar
  32. 32.
    Stahmeyer JT, Rossol S, Liersch S et al (2017) Cost-effectiveness of treating hepatitis C with sofosbuvir/ledipasvir in Germany. PLoS ONE 12:e169401CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Deterding K, Honer Zu Siederdissen C, Port K et al (2015) Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther 42:889–901CrossRefPubMedGoogle Scholar
  34. 34.
    Mettke F, Schlevogt B, Deterding K et al (2018) Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis. Aliment Pharmacol Ther 47:516–525CrossRefPubMedGoogle Scholar
  35. 35.
    Cornberg M, Petersen J, Schober A et al (2017) Real-world use, effectiveness and safety of anti-viral treatment in chronic hepatitis C genotype 3 infection. Aliment Pharmacol Ther 45:688–700CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Medizinische Hochschule HannoverHannoverDeutschland
  2. 2.Universitätsklinikum EssenEssenDeutschland

Personalised recommendations